Key points are not available for this paper at this time.
CD74–NRG1 fusions may represent a therapeutic opportunity for invasive mucinous lung adenocarcinomas, a tumor with no effective treatment that frequently presents with multifocal unresectable disease.
Fernandez‐Cuesta et al. (Mon,) studied this question.